NN 1406

Drug Profile

NN 1406

Alternative Names: NN1406; NNC0143-0406; NNC0143-0406 A; PI 406

Latest Information Update: 29 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novo Nordisk
  • Class Antihyperglycaemics; Insulins
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 04 Jul 2017 Novo Nordisk completes a phase I trial for Type-1 diabetes mellitus in Austria (NCT02938572)
  • 01 Oct 2016 Novo Nordisk initiates a phase I trial for Type-1 diabetes mellitus in Austria (NCT02938572)
  • 07 Sep 2016 Phase-I clinical trials in Type-2 diabetes mellitus (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top